WAVE Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at HC Wainwright

Key Points

• HC Wainwright initiated coverage of WAVE Life Sciences with a “strong-buy” rating and forecast a Q4 2027 loss of $0.28 per share. Analysts overall rate the stock “Moderate Buy,” with a consensus price target of $20.89.
• WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33 consensus estimate, while revenue of $13.16 million significantly exceeded expectations of $4.51 million.
• The company remains unprofitable, with analysts forecasting a full-year loss of $1.12 per share; its outlook depends heavily on clinical progress for RNA-editing candidate WVE-006 and managing ongoing cash-burn risks.

Stock analysts at HC Wainwright began coverage on shares of WAVE Life Sciences (NASDAQ:WVE - Get Free Report) in a note issued to investors on Wednesday, Zacks reports. The firm set a "strong-buy" rating on the stock. HC Wainwright also issued estimates for WAVE Life Sciences' Q4 2027 earnings at ($0.28) EPS.

Other research analysts also recently issued reports about the stock. Citigroup cut their target price on shares of WAVE Life Sciences from $24.00 to $19.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Wedbush set a $13.00 target price on WAVE Life Sciences in a research report on Friday, October 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. William Blair assumed coverage on shares of WAVE Life Sciences in a research report on Friday, October 16th. They set an "outperform" rating for the company. Finally, Leerink Partners set a $10.00 price objective on WAVE Life Sciences in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $20.89.

WAVE Life Sciences Price Performance

Shares of NASDAQ:WVE opened at $3.64 on Wednesday. The business has a 50-day moving average of $4.13 and a two-hundred day moving average of $7.60. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73. The stock has a market capitalization of $717.92 million, a P/E ratio of -3.34 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. As a group, research analysts expect that WAVE Life Sciences will post -1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adrian Rawcliffe sold 12,700 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Heidi Wagner sold 7,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the transaction, the director owned 44,930 shares in the company, valued at approximately $270,029.30. The trade was a 13.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 23,564 shares of company stock worth $132,476 over the last ninety days. Insiders own 24.34% of the company's stock.

Hedge Funds Weigh In On WAVE Life Sciences

A number of large investors have recently bought and sold shares of the stock. AlphaGrep UK Ltd bought a new position in WAVE Life Sciences in the second quarter worth $78,000. First Trust Advisors LP boosted its position in shares of WAVE Life Sciences by 15.7% during the first quarter. First Trust Advisors LP now owns 13,518 shares of the company's stock valued at $98,000 after buying an additional 1,830 shares during the last quarter. Chicago Partners Investment Group LLC bought a new stake in shares of WAVE Life Sciences in the first quarter worth approximately $124,000. Gabelli Funds LLC purchased a new stake in WAVE Life Sciences during the 1st quarter valued at $127,000. Finally, Seven Fleet Capital Management LP purchased a new stake in WAVE Life Sciences during the second quarter valued at $111,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33–$0.34 analyst consensus. Revenue of $13.16 million also substantially exceeded estimates of approximately $4.51 million, helping ease concerns about the company’s near-term financial performance. Wave Life Sciences Stock Rallies as Q3 Results Ease Loss Fears
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, providing a meaningful future catalyst if the program continues to generate positive data. WAVE Life Sciences Reports Third Quarter Results and Business Update
• Positive Sentiment: Management’s earnings call and business update provided investors with additional detail on the development pipeline and upcoming clinical milestones, supporting optimism around WVE-006 and the company’s broader RNA-editing platform. WAVE Life Sciences Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Oppenheimer reduced its price target to $29 from $32 but maintained an Outperform rating. The lower target is a modest valuation reset, while the unchanged rating indicates the analyst remains constructive on WVE’s long-term prospects. Oppenheimer Adjusts WAVE Life Sciences Price Target
• Negative Sentiment: Despite the earnings beat, WAVE remains unprofitable, reporting a quarterly loss and maintaining substantial cash-burn risk as it funds clinical development. Analysts continue to forecast a full-year loss, leaving the stock highly dependent on future trial progress and financing conditions. WAVE Life Sciences Reports Q3 Loss and Tops Revenue Estimates

About WAVE Life Sciences

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.